In-licensing is an important growth channel for pharmaceutical companies as they continue to seek more catalysts for growth. In-licensing is used to expand or consolidate a company’s position in a therapy area but can oftentimes be limited by internal restraints.
Common Barriers to In-Licensing: Capacity and Capability Constraints
Many times, companies are limited in in-licensing more clinically and commercially viable assets due to commercial capacity and capability constraints.
In fact, observations from recent due diligence efforts indicate companies eliminate at least 20-30% of potentially viable assets due to not having enough resources to commercialize the asset or not having the unique capabilities necessary to commercialize based on asset or market characteristics.
Overcome In-Licensing Hurdles to Accelerate Growth and Support Increased Valuations
By leveraging the robust and bespoke capabilities offered by EVERSANA™, there is a substantial opportunity to realize significant growth by drawing more commercial value from increased in-licensing activity. Partnering with EVERSANA allows companies to pursue more assets that may be strategically aligned with your organization, across any therapeutic modality, in any major pharmaceutical market.
Ready to learn more about in-licensing opportunities with EVERSANA? Schedule a time to talk to our experts today.
Faruk is a life sciences professional with extensive experience addressing a broad range of strategic issues, including corporate development, portfolio planning, and launch excellence.
Greg is EVERSANA’s Chief Revenue Officer and Head of Global Commercialization. He is responsible for accelerating the company’s growth and ensuring the success of all client commercialization efforts. With more than 25 years of…